In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Vladimira DurmanovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Iveta MikolaskovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.ORCID 0000-0003-4443-9069 Juraj JavorInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.ORCID 0000-0002-7741-5779 Agata OcenasovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.ORCID 0009-0002-4397-5310 Magda SuchankovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Boris KollarikDepartment of Urology, Bory Hospital, 841 03 Bratislava, Slovakia.
Milan ZvarikDepartment of Nuclear Physics and Biophysics, Faculty of Mathematics, Physics and Computer Science, Comenius University in Bratislava, 842 48 Bratislava, Slovakia.ORCID 0000-0002-0165-6066 Maria BucovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Luba HunakovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Funding
Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences VEGA 1/0092/22Slovak Research and Development Agency APVV-22-0231
6 · The paper itselfAbstract
Chronic inflammation contributes to bladder cancer (BC) development and progression through dysregulated cytokine signaling and tumor-immune interactions. This case-control study investigated associations between
Indexed as
Autonomic Nervous SystemChemokine CCL2Genetic Predisposition to DiseaseInterleukin-6Polymorphism, Single NucleotideTumor Necrosis Factor-alphaUrinary Bladder NeoplasmsVascular Endothelial Growth Factor AAgedCase-Control StudiesFemaleGenotypeHeart RateHumansMaleMiddle AgedCCL2 protein, humanChemokine CCL2IL6 protein, humanInterleukin-6TNF protein, humanTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AVEGFA protein, humanbladder cancercytokinesheart rate variabilityinflammationpolymorphismtumor grade
Identifiers
PMID42074005
PMCPMC13116236
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390